Cardiomyopathies
Alnylam’s Amvuttra Approved for ATTR Cardiomyopathy, Challenging Pfizer and BridgeBio
Amvuttra, vutrisiran, ATTR-CM, FDA approval, RNAi therapeutic, cardiomyopathy
BridgeBio’s Attruby Gains FDA Approval, Challenging Pfizer’s Tafamidis in ATTR-CM Treatment
Attruby, acoramidis, BridgeBio, ATTR-CM, tafamidis, Pfizer, FDA approval, transthyretin stabilizer, cardiomyopathy
Edgewise Therapeutics Sees 50% Stock Surge Following Positive Safety Data for Heart Disease Drug EDG-7500
Edgewise Therapeutics, EDG-7500, Heart Disease, Cardiomyopathy, Stock Surge, Safety Data, Camzyos Rival
Alnylam’s Vutrisiran Shows Promise in ATTR-CM Treatment, but Faces Competition
Alnylam, Vutrisiran, ATTR-CM, Phase 3 Trial, HELIOS-B, RNAi Therapeutics, Cardiomyopathy, Amyloidosis
Lexeo Therapeutics Reports Promising Early Data for Gene Therapy LX2006 in Friedreich Ataxia Cardiomyopathy
Lexeo Therapeutics, LX2006, Gene Therapy, Friedreich Ataxia, Cardiomyopathy, Clinical Trials, Rare Genetic Disorders
Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran
Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy
Cytokinetics’ Phase III Trials Show Promise in Challenging Cardiomyopathy Treatment Dominated by BMS
Cytokinetics, Phase III trials, cardiomyopathy, Bristol-Myers Squibb (BMS), heart failure treatment, myosin inhibitors, omecamtiv mecarbil, clinical data, heart muscle contraction, cardiovascular disease.